RXC007

DRUG2 trials

Sponsors

Redx Pharma Ltd

Conditions

FibrosisIPFIdiopathic Pulmonary FibrosisInflammationKidney DiseasesLiver DiseasesNon-alcoholic Steatohepatitis

Phase 1

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

CompletedNCT04931147

Redx Pharma LtdFibrosis, Idiopathic Pulmonary Fibrosis, Inflammation +3

Start: 2021-05-13End: 2023-03-08Updated: 2023-11-18

Phase 2

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Active, not recruitingNCT05570058

Redx Pharma LtdFibrosis, IPF

Start: 2022-09-08End: 2025-01-09Updated: 2024-08-23

Related Papers

Abstract 720: Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer

Cancer Research2024-03-22